News and Publications

Press Releases

Celares GmbH now part of Biosynth® Group Limited

Read more

Manufacturing authorization for conjugate vaccines

Read more

Agreement with German company Celares paves way for large-scale production of QPG-1029

Read more

Merck Millipore Adds Protein PEGylation to Portfolio of Services for Biopharmaceutical Industry through Collaboration with celares GmbH

Read more

celares GmbH establishes collaboration with NOF

Read more


Celares – From Development to Production

celares GmbH has outstanding technical know-how in the fields of synthetix chemistry, biotechnology and bioanalytics wich is complemented by a high level of experitse and many years of experience in the areas of polymer materials, modified protein drugs and PEGylation. (2016)

BioProcess Special Report

PEGylation of Biologics. A Multipurpose Solution. (2013)

BioTOPics 43 Biomaterials in Medicine

Increasingly, biomolecules are used for drug delivery, medical products are functionalised using biomolecules, and innovative biomaterials are created based on models from nature. (2012)

CampusNews 1/11

celares weltweit gefragt – Interview mit den Geschäftsführern der celares GmbH Günther Pätz, Dr. Ralf Krähmer und Dr. Frank Leenders. (2011)

Neuartige Wirkstoffe profitieren von etabliertem Polymer

DRUG DISCOVERY – Die Berliner Firma Celares bietet Hilfe bei der Formulierung biologischer Wirkstoffe und hat eine eigene Palette Polyethylenglykol-basierter Reagenzien zur Modifikation von Peptiden und Proteinen entwickelt. Zusammen mit Scil Proteins wurde gerade eine neuartige PEGylierungsmethode patentiert. (2009)

PEGylation of APIT

APIT (Aplysia punctata ink toxin) is a 60 kDa protein isolated from the defensive ink of the sea hare Aplysia punctata. In the meantime it is produced as a recombinant protein in bacteria. APIT kills tumor cells in an apoptosis independent manner. APIT possesses an L-amino acid oxidase activity that catalyzes the oxidative deamination of L-lysine and Larginine. (2007)

Highlights in der Produktion rekombinanter Proteine

Bereits zum dritten Mal fand vom 1. bis 3. März 2007 die Halle Conference in Halle an der Saale statt. Zentrale Themen waren die Entwicklung und Produktion neuer therapeutischer Proteinwirkstoffe und deren Verbesserung durch chemische Modifikation. (2007)

PEGylation technology and biopharmaceuticals

Simple modification with polyethylene glycol (PEG) is not only capable of improving the pharmacological properties of a drug, especially for peptide and protein therapeutics, but has also to be considered with regard to its life cycle extension. Dr Frank Leenders of celares GmbH describes PEGylation technologies and how they are impacting biopharmaceutical development. (2006)


How can we improve the efficiency of antigen specific tolerance induction? (2005)